Access to Investigational Medicines

Early Patient Access to Takeda Oncology Investigational Medicines

Takeda is committed to serving patients and as part of that commitment will provide access to investigational medicines for those who are determined by their physicians to have a critical unmet need.

For oncology patients who do not qualify for an ongoing clinical trial, and whose physician determines there is no comparable or satisfactory alternative therapy, Takeda may be able to provide the investigational medicine through a Named Patient Program (NPP) [provided applicable eligibility criteria are met]. An NPP is a compassionate use drug supply program under which medical practitioners can legally supply investigational drugs to eligible patients.

Requesting Access to Takeda Investigational Medicine

Licensed healthcare professionals in areas outside of the United States who are interested in the following Takeda investigational products may request further information using the below contact details:

Mifamurtide (MEPACT®)

IDIS Limited

Inquiries Outside of UK
Tel: +44 (0) 1932 824 123
Fax: +44 (0) 1932 824 323
Email: idisglobal@clinigengroup.com

Brentuximab vedotin (ADCETRIS®)

IDIS Limited

Tel: +44 (0) 1932 824 123
Fax: +44 (0) 1932 824 323
Email: idisglobal@clinigengroup.com

Ixazomib (NINLARO®)

Clinigen Group plc

Online Request: http://www.clinigengroup.com/cliniport

Email: {MAIL}

Country Telephone Number Fax Number
UK +44 1283 494 340 +44 1283 494 341
Belgium 065 250 307 +44 1283 494 341
France 0800 903 406 0805 109 994
Germany 069 2222 3413 0800 589 2457
Italy 800 977 669 800 977 686
Spain 800 600 217 800 600 218
Australia 1 800 614 796  
All other countries +44 1283 494 340 +44 1283 494 341